Published in Ann Oncol on April 01, 1994
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1996) 1.49
Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol (1998) 1.31
A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis (2002) 1.30
Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer (1998) 1.25
The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene (2009) 1.08
Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer (1997) 1.03
Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer (1997) 1.00
Perfusion computed tomography evaluation of angiogenesis in liver cancer. Eur Radiol (2010) 0.94
Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis. Br J Cancer (2008) 0.84
Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma. Mol Pathol (1997) 0.78
Modelling uveal melanoma. Br J Ophthalmol (1999) 0.75
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18
Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol (1999) 2.17
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol (2000) 2.11
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem (1998) 2.08
An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature (1988) 2.07
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet (1993) 2.03
Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93
Voltage dependence of junctional conductance in early amphibian embryos. Science (1979) 1.90
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89
Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ Res (1995) 1.84
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Gating of gap junction channels. Biophys J (1984) 1.70
The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (1990) 1.69
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer (2003) 1.67
Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol (1994) 1.66
hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer (2003) 1.65
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer (1992) 1.62
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res (2000) 1.60
New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene (2010) 1.60
Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer (1988) 1.59
Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res (1993) 1.58
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene (2000) 1.57
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57
Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res (1995) 1.56
The ubiquitin-proteasome pathway in cancer. Br J Cancer (1998) 1.56
Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A (1995) 1.54
Carboplatin or cisplatin? Lancet (1988) 1.53
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed) (1987) 1.52
Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer (1990) 1.52
O6-Methylguanine-DNA methyltransferase of human lymphoid cells: structural and kinetic properties and absence in repair-deficient cells. Cancer Res (1983) 1.52
Ways of escape: are all tumours angiogenic? Histopathology (2001) 1.48
Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol (1992) 1.48
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol (2003) 1.47
Gap junctional conductance: comparison of sensitivities to H and Ca ions. Proc Natl Acad Sci U S A (1982) 1.47
Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol (1997) 1.47
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer (1998) 1.46
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res (2001) 1.46
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol (1995) 1.45
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer (2004) 1.44
DNA repair in Escherichia coli mutants deficient in DNA polymerases I, II and-or 3. Proc Natl Acad Sci U S A (1974) 1.43
Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc Natl Acad Sci U S A (1988) 1.43
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat (2004) 1.43
Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol (1996) 1.42
Cross-linking of DNA induced by chloroethylnitrosourea is presented by O6-methylguanine-DNA methyltransferase. Nucleic Acids Res (1983) 1.42
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol (1989) 1.41
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol (1998) 1.41
Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res (2001) 1.41
Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol (1985) 1.41
Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol (1995) 1.40
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer (2004) 1.39
Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res (1995) 1.39